Claims
- 1. A pharmaceutical composition comprising a Reoviridae virus conjugated to a hydroxylated hydrocarbon dispersed in a pharmaceutically acceptable carrier.
- 2. The pharmaceutical composition of claim 1, wherein the Reoviridae virus is a reovirus.
- 3. The pharmaceutical composition of claim 2, wherein the reovirus is human serotype 3 reovirus.
- 4. The pharmaceutical composition of claim 1, wherein the hydroxylated hydrocarbon is polyethylene glycol.
- 5. The pharmaceutical composition of claim 1 further comprising a cell-targeting moiety.
- 6. The pharmaceutical composition of claim 4, wherein the targeting moiety is an antibody.
- 7. The pharmaceutical composition of claim 6, wherein the antibody is C225, Trastuzuab, ID5, PB3, TA-1, 4d5, Edrecolomab, CC49, Mc5, N901, CD56, MDX447, HMFG1, or IDEC-C2B8.
- 8. The pharmaceutical composition of claim 5, wherein the targeting moiety is a vascular endothelial penetration targeting peptide.
- 9. The pharmaceutical composition of claim 8, wherein the vascular endothelial penetration peptide is fibronectin attachment protein, alpha syndecin-1, HPV16L2 viral peptide or a laminin 5 gamma 2 chain fragment.
- 10. A pharmaceutical composition comprising a Reoviridae virus conjugated to a polycationic polymer dispersed in a pharmaceutically acceptable carrier.
- 11. The pharmaceutical composition of claim 10, wherein the Reoviridae virus is a reovirus.
- 12. The pharmaceutical composition of claim 11, wherein the reovirus is human serotype 3 reovirus.
- 13. The pharmaceutical composition of claim 10, wherein the polycationic polymer is polyethylene imine.
- 14. The pharmaceutical composition of claim 10 further comprising a cell-targeting moiety.
- 15. A method of treating a hyperproliferative disorder comprising administering to a patient an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon that is effective to treat the hyperproliferative disorder.
- 16. The method of claim 15, wherein the patient is human.
- 17. The method of claim 15, wherein the virus is administered via an alimentary route or a parenteral route.
- 18. The method of claim 17, wherein the parenteral route is intravenous.
- 19. The method of claim 17, wherein the parenteral route is intra-tumoral.
- 20. The method of claim 17, wherein the parenteral route is intraperitoneal or intrathecal.
- 21. The method of claim 15, wherein the Reoviridae virus is a reovirus.
- 22. The method of claim 21, wherein the reovirus is a human serotype 3 reovirus.
- 23. The method of claim 15, wherein the hydroxylated hydrocarbon is polyethylene glycol.
- 24. The method of claim 15, wherein the hyperproliferative disorder is further defined as cancer.
- 25. The method of claim 24, wherein the cancer comprises a neoplasm.
- 26. The method of claim 25, wherein the neoplasm is melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, leukemia, neuroblastoma, squamous cell, head, neck, gum, tongue, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder.
- 27. The method of claim 15, wherein the hyperproliferative disease is rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, or psoriasis.
- 28. The method of claim 15 further comprising administrating a chemotherapeutic agent.
- 29. The method of claim 15 further comprising administrating radiotherapy, hormonal therapy or immunotherapy.
- 30. A method of treating a hematopoietic neoplasm comprising administering to a patient an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon that is effective to treat the hematopoietic neoplasm.
- 31. The method of claim 30, wherein the hematopoietic neoplasm is selected from the group consisting of acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocyte leukemia, multiple myeloma or chronic lymphocytic leukemia, or other malignancy of hematologic origin.
- 32. The method of claim 30, wherein the patient is human.
- 33. The method of claim 30, wherein the virus is administered to the patient intravenously, intracerebrally or intrathecally.
- 34. The method of claim 30, wherein the Reoviridae virus is a reovirus.
- 35. The method of claim 34, wherein the reovirus is a human serotype 3 reovirus.
- 36. The method of claim 30, wherein the hydroxylated hydrocarbon is polyethylene glycol.
- 37. A method of treating a hyperproliferative disorder comprising administering to a patient an effective amount of a Reoviridae virus conjugated to a polycationic polymer that is effective to treat the hyperproliferative disorder.
- 38. The method of claim 37, wherein the polycationic polymer is polyethylene imine.
- 39. The method of claim 37, wherein the Reoviridae virus is a reovirus.
- 40. The method of claim 39, wherein the reovirus is a human serotype 3 reovirus.
- 41. The method of claim 30, wherein the hyperproliferative disorder is further defined as cancer.
- 42. The method of claim 37, wherein the cancer comprises a neoplasm.
- 43. The method of claim 42, wherein the neoplasm is melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, gum, tongue, leukemia, neuroblastoma, squamous cell, head, neck, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder.
- 44. The method of claim 37, wherein the hyperproliferative disease is rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, or psoriasis.
- 45. The method of claim 37 further comprising administrating a chemotherapeutic agent.
- 46. The method of claim 37 further comprising administrating radiotherapy, hormonal therapy or immunotherapy.
- 47. A method of lysing hyperproliferating cells comprising administering to a patient an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon that is effective to lyse the hyperproliferating cells.
- 48. The method of claim 47, wherein the hydroxylated hydrocarbon is polyethylene glycol.
- 49. The method of claim 47, wherein the hyperproliferating cells are cells of a neoplasm.
- 50. The method of claim 49, wherein the neoplasm is melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, gum, tongue, leukemia, neuroblastoma, head, neck, squamous cell, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder.
- 51. The method of claim 50, wherein leukemia is acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, juvenile myelomonocyte leukemia or multiple myeloma.
- 52. The method of claim 47, wherein the hyperproliferative disease is rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, or psoriasis.
- 53. A method of treating a neoplasm comprising administrating an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon and a targeting moiety that is effective to treat the neoplasm.
- 54. The method of claim 53, wherein the neoplasm is a solid neoplasm.
- 55. The method of claim 54, wherein the neoplasm is melanoma, non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, gum, tongue, neuroblastoma, head, neck, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder.
- 56. The method of claim 53, wherein the targeting factor is an antibody.
- 57. The method of claim 53, wherein the targeting factor is a vascular endothelial penetration peptide.
- 58. The method of claim 57, wherein the virus is administered to the patient intravenously, intra-tumorally, intracerebrally, intraperitoneally, intra-plurally, subcutaneously, orally, or intrathecally.
- 59. A method of inhibiting metastasis of a neoplasm in a patient comprising an administering an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon that is effective to inhibit metastasis.
- 60. The method of claim 59, wherein the hydroxylated hydrocarbon is polyethylene glycol.
- 61. A method of treating a patient with cancer comprising administering to the patient an effective amount of a Reoviridae virus conjugated to a hydroxylated hydrocarbon and administering at least one other anticancer treatment.
- 62. The method of claim 62, wherein the anticancer treatment is chemotherapy, immunotherapy, surgery, hormonal therapy, or radiotherapy.
- 63. The method of claim 62, wherein the cancer is non-small cell lung, small-cell lung, lung hepatocarcinoma, retinoblastoma, astrocytoma, gliobastoma, gum, tongue, leukemia, neuroblastoma, squamous cell, head, neck, breast, pancreatic, prostate, renal, bone, testicular, ovarian, mesothelioma, cervical, gastrointestinal, lymphoma, brain, colon, or bladder.
- 64. The method of claim 62, wherein the Reoviridae virus is a reovirus.
- 65. The method of claim 64, wherein the reovirus is a human serotype 3 reovirus.
- 66. The method of claim 62, wherein the hydroxylated hydrocarbon is polyethylene glycol.
Parent Case Info
[0001] This application claims priority to U.S. provisional application No. 60/310,206, which was filed Aug. 3, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60310206 |
Aug 2001 |
US |